← Back to Clinical Trials
Recruiting NCT04111692

NCT04111692 A Prospective Observational Study of Foam Sclerotherapy .

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT04111692
Status Recruiting
Phase
Sponsor Mayo Clinic
Condition Autosomal Dominant Polycystic Kidney
Study Type OBSERVATIONAL
Enrollment 100 participants
Start Date 2017-11-06
Primary Completion 2027-11

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 100 Years
Study Type OBSERVATIONAL

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 100 participants in total. It began in 2017-11-06 with a primary completion date of 2027-11.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

An observational prospective study to determine the impact of foam sclerotherapy of large, dominant kidney/liver cysts on quality of life outcomes and kidney/liver cyst volumes at up to 12 months of follow-up in patients with autosomal dominant polycystic kidney disease (ADPKD) and autosomal dominant polycystic liver disease (ADPLD).

Eligibility Criteria

Inclusion Criteria: * Age ≥18 years * Clinical diagnosis of ADPKD or ADPLD * 1-3 large, non-exophytic liver or kidney cyst * Compressive symptoms from dominant cyst Exclusion Criteria: * Age \<18 years * Absence of ADPKD or ADPLD * Largest cyst \<4cm in all 3 dimensions or largest cyst volume \<400cc * \>3 large, non-exophytic liver or kidney cyst(s) ≥4cm in all 3 dimensions (cyst volume ≥400cc) * Unwilling to comply with study follow-up protocol to 12 ± 1months post-FS * Lacking capacity to provide informed consent to FS of liver or kidney cysts * Pregnancy

Contact & Investigator

Central Contact

Cassie Howe, CRC

✉ howe.cassie@mayo.edu

📞 507-266-1230

Principal Investigator

Marie Hogan, MD, PhD

PRINCIPAL INVESTIGATOR

Mayo Clinic

Frequently Asked Questions

Who can join the NCT04111692 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 100 Years, studying Autosomal Dominant Polycystic Kidney. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT04111692 currently recruiting?

Yes, NCT04111692 is actively recruiting participants. Contact the research team at howe.cassie@mayo.edu for enrollment information.

Where is the NCT04111692 trial being conducted?

This trial is being conducted at Rochester, United States.

Who is sponsoring the NCT04111692 clinical trial?

NCT04111692 is sponsored by Mayo Clinic. The principal investigator is Marie Hogan, MD, PhD at Mayo Clinic. The trial plans to enroll 100 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology